261 related articles for article (PubMed ID: 37760602)
1. Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis.
Johnson RL; Ganesan S; Thangavelu A; Theophilou G; de Jong D; Hutson R; Nugent D; Broadhead T; Laios A; Cummings M; Orsi NM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760602
[TBL] [Abstract][Full Text] [Related]
2. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology.
Rousset-Rouviere S; Rochigneux P; Chrétien AS; Fattori S; Gorvel L; Provansal M; Lambaudie E; Olive D; Sabatier R
Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34199461
[TBL] [Abstract][Full Text] [Related]
3. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
[TBL] [Abstract][Full Text] [Related]
4. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
Maiorano BA; Maiorano MFP; Cormio G; Maglione A; Lorusso D; Maiello E
Front Oncol; 2022; 12():844801. PubMed ID: 35494078
[TBL] [Abstract][Full Text] [Related]
5. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.
Green AK; Feinberg J; Makker V
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32213091
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
Konstantinopoulos PA; Luo W; Liu JF; Gulhan DC; Krasner C; Ishizuka JJ; Gockley AA; Buss M; Growdon WB; Crowe H; Campos S; Lindeman NI; Hill S; Stover E; Schumer S; Wright AA; Curtis J; Quinn R; Whalen C; Gray KP; Penson RT; Cannistra SA; Fleming GF; Matulonis UA
J Clin Oncol; 2019 Oct; 37(30):2786-2794. PubMed ID: 31461377
[TBL] [Abstract][Full Text] [Related]
10. Dostarlimab for the treatment of advanced endometrial cancer.
Redondo A; Gallego A; Mendiola M
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):1-9. PubMed ID: 35184615
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in endometrial cancer.
Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; García de Santiago B; Casado Sáenz E
Crit Rev Oncol Hematol; 2021 May; 161():103306. PubMed ID: 33839243
[TBL] [Abstract][Full Text] [Related]
12. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Konstantinopoulos PA; Gockley AA; Xiong N; Krasner C; Horowitz N; Campos S; Wright AA; Liu JF; Shea M; Yeku O; Castro C; Polak M; Lee EK; Sawyer H; Bowes B; Moroney J; Cheng SC; Tayob N; Bouberhan S; Spriggs D; Penson RT; Fleming GF; Nucci MR; Matulonis UA
JAMA Oncol; 2022 Sep; 8(9):1317-1322. PubMed ID: 35900726
[TBL] [Abstract][Full Text] [Related]
14. A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer.
Tinker AV; Dhani NC; Ghatage P; McLeod D; Samouëlian V; Welch SA; Altman AD
Ther Adv Med Oncol; 2023; 15():17588359231157633. PubMed ID: 36950270
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer".
Gadducci A; Cosio S
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944775
[TBL] [Abstract][Full Text] [Related]
17. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
18. Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.
Mimura K; Shimomura A; Gota T; Ando K; Kawamura Y; Taniyama T; Oishi H; Shimizu C
Gynecol Oncol Rep; 2022 Dec; 44():101084. PubMed ID: 36277029
[TBL] [Abstract][Full Text] [Related]
19. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
20. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
Kasherman L; Ahrari S; Lheureux S
Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]